What treatment options are available for someone with an ER + breast cancer?

• A. Tamoxifen
• B. Aromatase inhibitors
• C. Chemotherapy
• D. Tamoxifen, aromatase inhibitors

Answer: (D)

ER-positive breast cancer grows in response to estrogen, so treatments that block estrogen’s effects or lower its availability are central. Tamoxifen works by binding to estrogen receptors in breast tissue, preventing estrogen from stimulating tumor cells. Aromatase inhibitors reduce estrogen production by blocking the aromatase enzyme, which is especially effective in postmenopausal women where most estrogen comes from this conversion.

In premenopausal women, tamoxifen is commonly used, and aromatase inhibitors are used mainly after suppressing ovarian function. Endocrine therapy with these agents is a primary approach to treat ER+ disease and is used to lower recurrence risk after surgery and to slow progression in advanced disease. Chemotherapy can be used in ER+ cases, but it targets rapidly dividing cells rather than estrogen signaling, and endocrine therapies are the key options tailored to ER positivity.

So the option that includes both tamoxifen and aromatase inhibitors reflects the main treatment approaches for ER+ breast cancer.